AbbVie Inc. reported its fourth-quarter earnings for 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.16, compared to the estimated $2.13, and revenue of $15.1 billion, exceeding the forecast of $14.84 billion. The company's newer immunology drugs, Skyrizi and Rinvoq, contributed significantly to the results, with Skyrizi generating revenue of £3.78 billion, above the estimated $3.57 billion, and Rinvoq bringing in $1.83 billion, surpassing the expected $1.71 billion. However, sales of Humira, AbbVie's flagship rheumatoid arthritis drug, fell short of expectations at $1.68 billion against an estimate of $1.93 billion, marking a 49% decline. AbbVie raised its long-term outlook for Skyrizi and Rinvoq, forecasting combined revenues of nearly $24 billion in 2025 and over $31 billion by 2027. The company provided a 2025 adjusted EPS guidance of $12.12 to $12.32, slightly below the consensus estimate of $12.13. AbbVie CEO Robert Michael stated that the company is entering 2025 with significant momentum, expecting net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity. Additionally, AbbVie is bolstering its pipeline through acquisitions, including an $8.7 billion deal for Cerevel Therapeutics. Following the earnings release, AbbVie's stock rose by approximately 4% in premarket trading, reflecting investor confidence in the company's future growth driven by its newer drugs.